CSF Soluble TREM2 Fragment Ratio as Priming State Indicator

Target: TREM2/ADAM10/17 Composite Score: 0.680 Price: $0.68 Citation Quality: Pending biomarkers Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
B
Composite: 0.680
Top 33% of 1166 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.70 Top 40%
C+ Evidence Strength 15% 0.58 Top 54%
B+ Novelty 12% 0.72 Top 47%
C+ Feasibility 12% 0.55 Top 53%
A Impact 12% 0.82 Top 20%
A Druggability 10% 0.88 Top 18%
A Safety Profile 8% 0.85 Top 17%
B+ Competition 6% 0.70 Top 41%
C+ Data Availability 5% 0.50 Top 69%
C+ Reproducibility 5% 0.52 Top 66%
Evidence
3 supporting | 2 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.75
Convergence
0.00 F 6 related hypothesis share this target

From Analysis:

What biomarkers can reliably detect microglial priming states in living patients before neurodegeneration?

The debate focused on therapeutic targets but did not address how to identify patients in the optimal treatment window. Without reliable biomarkers for microglial priming, clinical translation of these hypotheses remains problematic. Source: Debate session sess_SDA-2026-04-04-gap-20260404-microglial-priming-early-ad (Analysis: SDA-2026-04-04-gap-20260404-microglial-priming-early-ad)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin
Score: 0.730 | Target: CHI3L1/TREM2/NRGN
CSF YKL-40 as a Priming-Specific Chitinase Marker
Score: 0.710 | Target: CHI3L1/YKL-40
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming
Score: 0.560 | Target: P2RX7/NLRP3
TSPO PET Kinetic Modeling for Priming State Discrimination
Score: 0.530 | Target: TSPO
Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming
Score: 0.520 | Target: Epigenetic landscape (TLR4, NLRP3, IL1B regulatory regions)
CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping
Score: 0.500 | Target: CX3CR1

→ View full analysis & all 7 hypotheses

Description

Site-specific TREM2 fragment ratios (N-terminal vs. C-terminal) distinguish homeostatic from priming-phase microglia. Reflects TREM2 shedding by ADAM10/17 proteases, which is regulated by microglial activation state. Direct mechanistic linkage to TREM2 biology enables alignment with active TREM2-targeted therapeutic programs, though the required mass spectrometry assay does not yet exist.

No AI visual card yet

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.70 (15%) Evidence 0.58 (15%) Novelty 0.72 (12%) Feasibility 0.55 (12%) Impact 0.82 (12%) Druggability 0.88 (10%) Safety 0.85 (8%) Competition 0.70 (6%) Data Avail. 0.50 (5%) Reproducible 0.52 (5%) 0.680 composite
5 citations 2 with PMID Validation: 0% 3 supporting / 2 opposing
For (3)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
1
MECH 3CLIN 1GENE 1EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
CSF sTREM2 increases in early symptomatic ADSupportingCLIN----PMID:27991925-
TREM2 variants alter microglial response to amyloi…SupportingGENE----PMID:28165504-
TREM2 is high-value target with active development…SupportingMECH------
Proposed mass spectrometry assay for site-specific…OpposingMECH------
Biphasic sTREM2 pattern adds temporal complexity; …OpposingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 3

CSF sTREM2 increases in early symptomatic AD
TREM2 variants alter microglial response to amyloid plaques
TREM2 is high-value target with active development programs (Biogen, AbbVie, Denali)

Opposing Evidence 2

Proposed mass spectrometry assay for site-specific fragments does not exist; requires 1-2 years development
Biphasic sTREM2 pattern adds temporal complexity; fragment ratio mapping to priming states unestablished
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-22 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Biomarker Hypotheses for Detecting Microglial Priming States

Hypothesis 1: TSPO PET Kinetic Modeling for Priming State Discrimination

Title: Distinguishing primed from dystrophic microglia using TSPO PET with compartmental modeling

Mechanism: TSPO expression increases with microglial activation, but quantitative metrics (distribution volume VT, binding potential BP) may reveal distinct kinetic signatures between surveillance (baseline), primed (heightened sensitivity), and fully activated states. Primed microglia may show intermediate TSPO availability.

**Target Gene/Prot

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Microglial Priming Biomarker Hypotheses

Hypothesis 1: TSPO PET Kinetic Modeling

Specificity Crisis. TSPO is expressed on microglia, astrocytes, endothelial cells, and infiltrating peripheral immune cells. TSPO PET measures a composite signal from heterogeneous cell populations, making it fundamentally unable to distinguish microglial-specific priming states. Post-mortem validations correlating TSPO+ cells with disease progression cannot disentangle this cellular ambiguity for in vivo application.

The "Intermediate Signal" Problem. The hypo

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Feasibility Assessment: Microglial Priming Biomarkers

Executive Summary

The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessible without biomarkers to define the treatment-eligible population. The biomarker hypotheses range from near-term clinical feasibility (Hypotheses 2, 5, 6) to speculative targets requiring extensive development (Hypotheses 4, 7). The integration of clinical pragmatism with mechanistic specificity determines which hypotheses merit prioritization.

Comparative Feasibility Matrix

| Hypothesi

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.670.680.69 0.70 0.66 2026-04-222026-04-222026-04-22 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (1)

0
Active
0
Completed
0
Total Enrolled
Untitled Trial Unknown
Unknown ·

📚 Cited Papers (2)

Paper:27991925
No extracted figures yet
Paper:28165504
No extracted figures yet

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Related Hypotheses

Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin
Score: 0.730 | biomarkers
CSF YKL-40 as a Priming-Specific Chitinase Marker
Score: 0.710 | biomarkers
P2X7R PET Imaging for NLRP3 Inflammasome-Associated Priming
Score: 0.560 | biomarkers
TSPO PET Kinetic Modeling for Priming State Discrimination
Score: 0.530 | biomarkers
Blood Monocyte Epigenetic Signature as Surrogate for Microglial Priming
Score: 0.520 | biomarkers

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 TREM2 — PDB 5UD7 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What biomarkers can reliably detect microglial priming states in living patients before neurodegeneration?

biomarkers | 2026-04-06 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)